Traders should monitor for the upcoming regulatory update in Q2 2026, which could significantly impact stock volatility depending on the FDA's feedback and path forward for tab-cel approval.
Price Chart
Executive Summary
Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for the Biologics License Application of tabelecleucel (tab-cel), developed with partner Pierre Fabre Pharmaceuticals. The company expects to provide a regulatory update in the second quarter of 2026.
Key Facts
- Atara Biotherapeutics announced a scheduled Type A meeting with the FDA on March 12, 2026.
- The meeting will address the Complete Response Letter (CRL) for the Biologics License Application (BLA) of tabelecleucel (tab-cel).
- The BLA is held by partner Pierre Fabre Pharmaceuticals, with Atara's support.
- The purpose is to discuss resubmission with additional efficacy data collected since the original submission.
- A regulatory update is anticipated in the second quarter of 2026.
Financial Impact
No immediate financial impact disclosed; potential future revenue depends on successful BLA resubmission and approval.
Risk Factors
- FDA may require additional clinical data or trials, delaying approval.
- Resubmission may not result in approval, risking further regulatory setbacks.
- Atara's market cap remains low ($45M), indicating high sensitivity to binary regulatory outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-103127 |
| Document: 0001193125-26-103127-index-headers.html | 0001193125-26-103127 |
| Document: 0001193125-26-103127.txt | 0001193125-26-103127 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 26, 2026 14w ago | 8-K | $11.17 $8.93 | ▼ −20.05% | ▼ −24.44% | $9.48 (−15.13%) |
Jun 15, 2026 15w ago | 3 | $9.62 $9.89 | ▲ +2.81% | ▲ +1.81% | $9.48 (−1.46%) |
May 7, 2026 21w ago | 8-K | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
May 7, 2026 21w ago | Insider Cluster | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
Apr 24, 2026 23w ago | DEFA14A | $4.99 $8.13 | ▲ +62.83% | ▲ +58.05% | $9.48 (+89.98%) |
Mar 17, 2026 28w ago | S-3 | $5.00 $10.46 | ▲ +109.20% | ▲ +97.67% | $9.48 (+89.60%) |
Mar 12, 2026 29w ago | 8-K | $6.90 $9.92 | ▲ +43.77% | ▲ +33.07% | $9.48 (+37.39%) |
Mar 3, 2026 30w ago | 8-K | $5.42 $10.54 | ▲ +94.46% | ▲ +84.15% | $9.48 (+74.91%) |
Mar 2, 2026 30w ago | Insider Cluster | $4.91 $9.61 | ▲ +95.72% | ▲ +86.40% | $9.48 (+93.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access